These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 38035276)
1. Treatment of Parkinson's disease with biologics that penetrate the blood-brain barrier via receptor-mediated transport. Pardridge WM Front Aging Neurosci; 2023; 15():1276376. PubMed ID: 38035276 [TBL] [Abstract][Full Text] [Related]
2. Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody. Pardridge WM Expert Opin Drug Deliv; 2015 Feb; 12(2):207-22. PubMed ID: 25138991 [TBL] [Abstract][Full Text] [Related]
3. IgG Fusion Proteins for Brain Delivery of Biologics via Blood-Brain Barrier Receptor-Mediated Transport. Boado RJ Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890374 [TBL] [Abstract][Full Text] [Related]
4. Delivery of Biologics Across the Blood-Brain Barrier with Molecular Trojan Horse Technology. Pardridge WM BioDrugs; 2017 Dec; 31(6):503-519. PubMed ID: 29067674 [TBL] [Abstract][Full Text] [Related]
5. Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier. Pardridge WM Front Drug Deliv; 2023; 3():. PubMed ID: 37583474 [TBL] [Abstract][Full Text] [Related]
6. Drug targeting to the brain. Pardridge WM Pharm Res; 2007 Sep; 24(9):1733-44. PubMed ID: 17554607 [TBL] [Abstract][Full Text] [Related]
7. Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein. Boado RJ; Hui EK; Lu JZ; Zhou QH; Pardridge WM J Biotechnol; 2010 Mar; 146(1-2):84-91. PubMed ID: 20100527 [TBL] [Abstract][Full Text] [Related]
8. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Pardridge WM; Boado RJ Methods Enzymol; 2012; 503():269-92. PubMed ID: 22230573 [TBL] [Abstract][Full Text] [Related]
11. Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse. Boado RJ; Hui EK; Lu JZ; Pardridge WM J Pharmacol Exp Ther; 2010 Jun; 333(3):961-9. PubMed ID: 20233799 [TBL] [Abstract][Full Text] [Related]
12. Biologic TNFα-inhibitors that cross the human blood-brain barrier. Pardridge WM Bioeng Bugs; 2010; 1(4):231-4. PubMed ID: 21327054 [TBL] [Abstract][Full Text] [Related]
13. Single domain antibody-based vectors in the delivery of biologics across the blood-brain barrier: a review. Gao Y; Zhu J; Lu H Drug Deliv Transl Res; 2021 Oct; 11(5):1818-1828. PubMed ID: 33155179 [TBL] [Abstract][Full Text] [Related]
14. Strategies to identify, engineer, and validate antibodies targeting blood-brain barrier receptor-mediated transcytosis systems for CNS drug delivery. Choi ES; Shusta EV Expert Opin Drug Deliv; 2023; 20(12):1789-1800. PubMed ID: 38007619 [TBL] [Abstract][Full Text] [Related]
15. Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins. Pardridge WM Adv Drug Deliv Rev; 2022 May; 184():114234. PubMed ID: 35307484 [TBL] [Abstract][Full Text] [Related]
17. Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier. Lajoie JM; Shusta EV Annu Rev Pharmacol Toxicol; 2015; 55():613-31. PubMed ID: 25340933 [TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibody-glial-derived neurotrophic factor fusion protein penetrates the blood-brain barrier in the mouse. Zhou QH; Boado RJ; Lu JZ; Hui EK; Pardridge WM Drug Metab Dispos; 2010 Apr; 38(4):566-72. PubMed ID: 20075191 [TBL] [Abstract][Full Text] [Related]
19. Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. Pardridge WM Bioconjug Chem; 2008 Jul; 19(7):1327-38. PubMed ID: 18547095 [TBL] [Abstract][Full Text] [Related]
20. Kinetics of Blood-Brain Barrier Transport of Monoclonal Antibodies Targeting the Insulin Receptor and the Transferrin Receptor. Pardridge WM Pharmaceuticals (Basel); 2021 Dec; 15(1):. PubMed ID: 35056060 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]